Construction and evaluation of sarcopenia risk prediction model for patients with diabetes: a study based on the China health and retirement longitudinal study (CHARLS)

构建和评价糖尿病患者肌少症风险预测模型:基于中国健康与养老纵向研究(CHARLS)的研究

阅读:1

Abstract

PURPOSE: Sarcopenia is a common complication of diabetes. Nevertheless, precise evaluation of sarcopenia risk among patients with diabetes is still a big challenge. The objective of this study was to develop a nomogram model which could serve as a practical tool to diagnose sarcopenia in patients with diabetes. METHODS: A total of 783 participants with diabetes from China Health and Retirement Longitudinal Study (CHARLS) 2015 were included in this study. After oversampling process, 1,000 samples were randomly divided into the training set and internal validation set. To mitigate the overfitting effect caused by oversampling, data of CHARLS 2011 were utilized as the external validation set. Least absolute shrinkage and selection operator (LASSO) regression analysis and multivariate logistic regression analysis were employed to explore predictors. Subsequently, a nomogram was developed based on the 9 selected predictors. The model was assessed by area under receiver operating characteristic (ROC) curves (AUC) for discrimination, calibration curves for calibration, and decision curve analysis (DCA) for clinical efficacy. In addition, machine learning models were constructed to enhance the robustness of our findings and evaluate the importance of the predictors. RESULTS: 9 factors were selected as predictors of sarcopenia for patients with diabetes. The nomogram model exhibited good discrimination in training, internal validation and external validation sets, with AUC of 0.808, 0.811 and 0.794. machine learning models revealed that age and hemoglobin were the most significant predictors. Calibration curves and DCA illustrated excellent calibration and clinical applicability of this model. CONCLUSION: This comprehensive nomogram presented high clinical predictability, which was a promising tool to evaluate the risk of sarcopenia in patients with diabetes.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。